New Study Finds Additional Evidence that Statin Drugs May Help Slow Mental Decline in the...

HASBROUCK HEIGHTS, N.J. -- Nymox (NASDAQ: NYMX) Has Global Patent Rights for Statin Drugs for the Treatment and Prevention of Alzheimer's Disease

A second new study (reported in the latest issue of Neurology (November, 2005; 65:1388-1394)) has found evidence that statin use was associated

with a reduction in cognitive decline in the elderly. Researchers in the Cardiovascular Health Study Collaborative Research Group monitored the cognitive abilities of 3,334 people over the age of 65 without dementia for an average of seven years and found that regular statin use was associated with a rate of cognitive decline less than half of that of untreated patients.

These new results published in Neurology (the official scientific journal of the American Academy of Neurology) follow on other positive results concerning Alzheimer's Disease (AD) and statin drugs which were released last week. In the first study, statins were found to slow the progression of Alzheimer's disease (AD) in a new three year study of 342 AD patients (J. Neurol. Neurosurg. Psychiatry 2005; 76:1624-1629). Researchers in France compared AD patients taking cholesterol-lowering medication including statins to AD patients with unmedicated high cholesterol levels and to AD patients with normal cholesterol. They found that the use of cholesterol-lowering medication significantly slowed the cognitive decline that is the hallmark of AD as compared to both the unmedicated high cholesterol group and the normal cholesterol group.

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) holds U.S. and global patent rights for the use of statin drugs for the prevention and treatment of AD.

Statins are a class of cholesterol-lowering drugs that are the biggest-selling prescription pills in pharmaceutical history with estimated 2004 global sales of up to $26 billion. Alzheimer's disease is the leading cause of dementia in the elderly, afflicting an estimated 4.5 million people in the U.S. alone.

The potential use of statins to treat Alzheimer's disease (AD) has been widely reported in the peer-reviewed medical literature, both in terms of clinical data, (such as J Neurol Neurosurg Psychiatry (2005; 76:1624-1629); The Lancet Neurology (2005; 4:521-2); Arch Neurol (2005; 62:1047-51); Neurology (2005; 64:1531-8); Arch Neurol (2005; 62:753-7); J Neurol Sci (2005; 229-230:147-50); Curr Opin Lipid (2005; 16:619-623); Arch Gen Psychiatry (2005; 62:217-24)) and possible mechanisms through which statins may prevent or slow the progression of Alzheimer's disease (such as J Neurosci Res (2005; 82:10-19); J Biol Chem (2005; M505268200); PLoS Med (2005; 2:e18); J Neurosci (2005; 25:299-307)).

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.